Emergent BioSolutions Inc. announced that the Biomedical Advanced Research and Development Authority (BARDA) has executed a contract modification for the second option period, valued at approximately $16.7 million. This funding is for drug product process and analytical testing validation and long-term stability for Ebanga (ansuvimab-zykl), an Ebola treatment.
Ebanga is indicated for the treatment of infection caused by Zaire Ebola virus. This option is part of an existing 10-year contract that includes a base period and two option periods for advanced development, totaling approximately $118 million, along with procurement options valued at up to $583 million over five years.
Under the terms of the contract, Emergent will complete activities to advance Ebanga's development through post-licensure commitments, including manufacturing scale-up, technology transfer, stability studies, and the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.